ATLAS-UC
Brief description of study
To evaluate the efficacy, safety, and tolerability of multiple does strengths of MK-7240 IV infusion and subcutaneous injection compared to Placebo as assessed by the proportion of participants achieving clinical remission per Modified Mayo Score, endoscopic improvements, at designated time points. Participants aged 16 to 75 years (inclusive) with moderately or severely active ulcerative colitis.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
